Sun Pharma Advanced Research Co (NSE:SPARC) EBIT : ₹-4,053.6 Mil (TTM As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co EBIT?

Sun Pharma Advanced Research Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₹-1,060.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-4,053.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sun Pharma Advanced Research Co's annualized ROC % for the quarter that ended in Sep. 2024 was %. Sun Pharma Advanced Research Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sun Pharma Advanced Research Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -5.83%.

Sun Pharma Advanced Research Co EBIT Historical Data

The historical data trend for Sun Pharma Advanced Research Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co EBIT Chart

Sun Pharma Advanced Research Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

-3,097.29

-1,404.89

-1,900.67

-2,149.49

-3,856.37

Sun Pharma Advanced Research Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-861.60	-993.90	-1,049.97	-949.40	-1,060.30

Competitive Comparison of Sun Pharma Advanced Research Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sun Pharma Advanced Research Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's EV-to-EBIT falls into.

Sun Pharma Advanced Research Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4,053.6 Mil.

Sun Pharma Advanced Research Co (NSE:SPARC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sun Pharma Advanced Research Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-4242.8 * ( 1 - -0.15% )	/	( (0	+	0)	/ 1 )
=	-4249.1642	/	0
=	%

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sun Pharma Advanced Research Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4241.2	/	( ( (0 + max(0, 0))	+	(0 + max(0, 0)) )	/	1 )
=	-4241.2	/	( ( 0	+	0 )	/	1 )
=	-4241.2	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sun Pharma Advanced Research Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-4053.573	/	69542.517
	=	-5.83 %

Sun Pharma Advanced Research Co EBIT Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharma Advanced Research Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (NSE:SPARC) » Definitions » EBIT

Traded in Other Exchanges

532872:India

Address

Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093

Website

https://www.sparc.life

Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines